Thomas Schinecker

New Capabilities

As of September 2026: Oversees the Tam-Peli license and ex-China development

Two rival antibody-drug conjugates just beat the standard of care in relapsed small-cell lung cancer. Roche-partnered Tam-Peli held median survival at 13.3 months; GSK's competitor got 18.5. Both faced the same decades-old chemotherapy — and that five-month gap is the story.

Updated Sep 14

New Capabilities

As of August 2026: Led development of two FDA-cleared blood tests (pTau181, pTau217)

Alzheimer's diagnosis used to require a $5,000 brain scan or a painful spinal tap. As of August 2026, the FDA has cleared four blood tests for the disease, from Roche's Elecsys pTau217 to C2N's PrecivityAD2, approved for adults as young as 40.

Updated Aug 25